BioMed Research International

Research Article

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

Table 3

Correlation between mutations detected in primary tumor or relapse tissue and PFS on everolimus and exemestane.
Mutations in primary tumor or relapse tissue PFS (months)
Patient 1wild type3
Patient 2mutated (BRAF)6
Patient 3wild type4
Patient 4wild type5
Patient 5wild type2
Patient 6mutated (PIK3CA; AKT1)15
Patient 7mutated (FBX4; PIK3CA; KIT)3
Patient 8wild type17
Patient 9mutated (TP53)1
Patient 10mutated (AKT1)3
Patient 11wild type5
Patient 12wild type9
Patient 13mutated (AKT1)2
Patient 14wild type9
Patient 15mutated (KIT)3
Patient 16wild type8
Patient 17wild type13
Patient 18mutated (MAP2K1; FBXW7)6
Patient 19wild type5
Patient 20mutated (CTNNB1)8
Patient 21wild type12
Patient 22mutated (FBXW7)5
Patient 23wild type5
Patient 24wild type13
Patient 25wild type2